Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach

A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C

(2015) Marilyn Huckans et al.   JOURNAL OF PSYCHOSOMATIC RESEARCH

Cost of treating hepatitis C in Germany

(2014) Jona T. Stahmeyer et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation

(2014) D Hartwell et al.   HEALTH TECHNOLOGY ASSESSMENT

Sticker shock and the price of new therapies for hepatitis C: Is it worth it?

(2014) Nancy S. Reau et al.   HEPATOLOGY

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

(2014) Liesl M. Hagan et al.   HEPATOLOGY

Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)

(2014) Sylvie Deuffic-Burban et al.   JOURNAL OF HEPATOLOGY

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

(2014) H. Razavi et al.   JOURNAL OF VIRAL HEPATITIS

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

(2014) Eric Lawitz et al.   LANCET

Cost-Utility Analysis of Simeprevir With Peginterferon + Ribavirin (SMV/PR) in the Management of Genotype 1 (G1) and 4 (G4) Hepatitis C Virus (HCV) Infection; from the Perspective of the Uk National Health Service (NHS)

(2014) K.Y. Westerhout et al.   VALUE IN HEALTH

Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation

(2013) Cornelia Henschke et al.   HEALTH POLICY

845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY

(2013) J.P. Lalezari et al.   JOURNAL OF HEPATOLOGY

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients

(2013) Zobair M. Younossi et al.   JOURNAL OF HEPATOLOGY

Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences

(2011) Marion Danner et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

(2011) Markus Cornberg et al.   LIVER INTERNATIONAL

Reflections on the Changing Face of German Pharmaceutical Policy

(2011) Andreas Gerber et al.   PHARMACOECONOMICS

The efficiency frontier approach to economic evaluation: will it help German policy making?

(2010) Werner B. F. Brouwer et al.   HEALTH ECONOMICS

The efficiency frontier approach to economic evaluation of health-care interventions

(2010) J. Jaime Caro et al.   HEALTH ECONOMICS

Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods

(2010) Mark Sculpher et al.   HEALTH ECONOMICS

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis

(2010) Ana-Carolina Cardoso et al.   JOURNAL OF HEPATOLOGY

Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response

(2009) Uwe Siebert et al.   PHARMACOECONOMICS